Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PLUR Stock Forecast 2026-2027
$3.13
Current Price
$28.96M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PLUR Price Targets
+283.4%
To High Target of $12.00
+283.4%
To Median Target of $12.00
+283.4%
To Low Target of $12.00
PLUR Price Momentum
+5.0%
1 Week Change
+1.6%
1 Month Change
-30.0%
1 Year Change
+4.7%
Year-to-Date Change
-56.1%
From 52W High of $7.13
+11.0%
From 52W Low of $2.82
📊 TOP ANALYST CALLS
Did PLUR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Pluri is one of their latest high-conviction picks.
Latest PLUR Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, PLUR has a bullish consensus with a median price target of $12.00 (ranging from $12.00 to $12.00). The overall analyst rating is N/A (N/A/10). Currently trading at $3.13, the median forecast implies a 283.4% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matthew Venezia at Alliance Global Partners, projecting a 283.4% upside. Conversely, the most conservative target is provided by Matthew Venezia at Alliance Global Partners, suggesting a 283.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PLUR Analyst Ratings
1
Buy
0
Hold
0
Sell
PLUR Price Target Range
Low
$12.00
Average
$12.00
High
$12.00
Current: $3.13
Latest PLUR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PLUR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 2, 2025 | Alliance Global Partners | Matthew Venezia | Buy | Initiates | $12.00 |
Pluri Inc. (PLUR) Competitors
The following stocks are similar to Pluri based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pluri Inc. (PLUR) Financial Data
Pluri Inc. has a market capitalization of $28.96M with a P/E ratio of -0.8x. The company generates $1.33M in trailing twelve-month revenue with a 49.0% profit margin.
Revenue growth is -3.1% quarter-over-quarter, while maintaining an operating margin of -2,009.5% and return on equity of +2,610.8%.
Valuation Metrics
Market Cap
$28.96M
Enterprise Value
$53.12M
P/E Ratio
-0.8x
PEG Ratio
0.0x
Price/Sales
21.3x
Growth & Margins
Revenue Growth (YoY)
-3.1%
Gross Margin
+36.4%
Operating Margin
-2,009.5%
Net Margin
+49.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+52.0%
Current Ratio
0.5x
Debt/Equity
-6.1x
ROE
+2,610.8%
ROA
-42.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Pluri Inc. (PLUR) Business Model
About Pluri Inc.
What They Do
Develops cell-based therapeutics for medical conditions.
Business Model
Pluri Inc. generates revenue by leveraging its proprietary 3D cell culture platforms to develop innovative therapies for regenerative medicine. The company focuses on creating scalable solutions that can be applied across various medical fields, including orthopedics and cardiovascular health, thus tapping into a diverse market for cell-based treatments.
Additional Information
With a strong emphasis on research and development, Pluri Inc. is positioned at the forefront of biotechnology innovation, aiming to address significant unmet medical needs. Their commitment to advanced technology in tissue engineering and organ regeneration highlights their potential to transform treatment approaches for both chronic and acute health issues on a global scale.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
127
CEO
Mr. Yaacov Yanay
Country
Israel
IPO Year
2019
Website
www.pluri-biotech.comPluri Inc. (PLUR) Latest News & Analysis
Latest News
Quick Summary
Pluri, Inc. (Nasdaq, TASE: PLUR) announced an expansion of its 2024 manufacturing agreement with Remedy Cell, which focuses on stem cell-derived therapeutics for fibrotic conditions.
Why It Matters
Pluri's expanded manufacturing agreement with Remedy Cell signals growth potential and innovation in biopharmaceuticals, which could enhance revenue and market position, attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
7 months ago
Quick Summary
BrainStorm Cell Therapeutics (NASDAQ: BCLI) has signed a Letter of Intent with Minaris Advanced Therapies for the manufacturing of NurOwn® for an upcoming clinical trial, marking a strategic collaboration.
Why It Matters
The LOI with Minaris for manufacturing NurOwn® signals progress in BrainStorm's clinical trials, potentially enhancing its market position and investor confidence in future growth.
Source: PRNewsWire
Market Sentiment:
Neutral
Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.
8 months ago
Quick Summary
Pluri has acquired a 71% stake in Kokomodo Ltd., combining its mass-scale cell production expertise with Kokomodo's capabilities.
Why It Matters
The acquisition enhances Pluri's capabilities, potentially boosting growth and market position, which could lead to increased investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness
10 months ago
Quick Summary
Pluri Inc. has signed an exclusive collaboration with Hemafund to address Ukraine's need for radiation countermeasures, potentially generating over $100 million in value.
Why It Matters
The collaboration could drive significant revenue growth for Pluri Inc., enhancing its market position and investor confidence, particularly in the biotech sector amid geopolitical challenges.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution
10 months ago
Quick Summary
A leading food industry company has partnered with Ever After Foods to advance the development of the cultivated meat market, indicating growth potential in this sector.
Why It Matters
Collaboration in cultivated meat signals growth in a sustainable food sector, potentially increasing market share and investor interest in alternative proteins, impacting food stocks positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition
11 months ago
Quick Summary
Pluri Inc. announced a $6.5 million strategic investment led by Alejandro Weinstein, who will join its Board. The company also acquired a 71% stake in AgTech firm Kokomodo for $4.5 million in shares.
Why It Matters
Pluri's $6.5 million investment and acquisition of Kokomodo enhance its market position in sustainable food tech, potentially driving growth and increasing shareholder value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PLUR Stock
What is Pluri Inc.'s (PLUR) stock forecast for 2026?
Based on our analysis of 1 Wall Street analysts, Pluri Inc. (PLUR) has a median price target of $12.00. The highest price target is $12.00 and the lowest is $12.00.
Is PLUR stock a good investment in 2026?
According to current analyst ratings, PLUR has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.13. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PLUR stock?
Wall Street analysts predict PLUR stock could reach $12.00 in the next 12 months. This represents a 283.4% increase from the current price of $3.13. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pluri Inc.'s business model?
Pluri Inc. generates revenue by leveraging its proprietary 3D cell culture platforms to develop innovative therapies for regenerative medicine. The company focuses on creating scalable solutions that can be applied across various medical fields, including orthopedics and cardiovascular health, thus tapping into a diverse market for cell-based treatments.
What is the highest forecasted price for PLUR Pluri Inc.?
The highest price target for PLUR is $12.00 from Matthew Venezia at Alliance Global Partners, which represents a 283.4% increase from the current price of $3.13.
What is the lowest forecasted price for PLUR Pluri Inc.?
The lowest price target for PLUR is $12.00 from Matthew Venezia at Alliance Global Partners, which represents a 283.4% increase from the current price of $3.13.
What is the overall PLUR consensus from analysts for Pluri Inc.?
The overall analyst consensus for PLUR is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are PLUR stock price projections?
Stock price projections, including those for Pluri Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 8:12 PM UTC